Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis: a prospective, observational real-life study
V. 171 N. 4 (2020), Research article
V. 171 N. 4 (2020)

Benefit of a topic ointment as co-medication with biologic drugs for the management of moderate-severe psoriasis: a prospective, observational real-life study: doi: 10.7417/CT.2020.2234

Research article
Pubblicato 2020-07-10
N. Bernardini
Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Rome, Italy
N. Skroza
Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Rome, Italy
E. Tolino
Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Rome, Italy
A. Marchesiello
Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Rome, Italy
A. Mambrin
Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Rome, Italy
V. Balduzzi
Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Rome, Italy
S. Michelini
Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Rome, Italy
P. Maddalena
Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Rome, Italy
S. Volpe
Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Rome, Italy
I. Proietti
Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Rome, Italy
C. Potenza
Dermatology Unit “D. Innocenzi”, Polo Pontino, Sapienza University of Rome, Rome, Italy
PDF

Parole chiave

Psoriasis
HIV
Psoriasis treatment

Abstract

Background
Psoriasis is a multifactorial chronic inflammatory skin disease characterized by erythemato-squamous lesions with a chronic relapsing course. The desease clinical activity (PASI) and the patient’s quality of life (DLQI) are the main elements to assess for setting up a correct therapeutic management.

Objective
The aim of the study was to evaluate the management of the patient with moderate-severe psoriasis in therapy with biological drugs and to establish the difference in the achievement of PASI 90 and DLQI 0-1 between a group of patients treated with only biological drugs and a group of patients receiving biologic therapy in combination with a topical ointment.

Methods
We conducted a prospective, observational real-life study enrolling 60 patients with moderate to severe psoriasis and divided in two groups: Group A patients treated with biological drugs, Group B patiens treated with biological drugs in association with an ointment composed of betamethasone, salicylic acid and ammonium sulpho-ichtyolate, applied 2 times a day. PASI and DLQI were evaluated at study beginning (T0) for both study groups, after 12 weeks (T3) for sample in therapy with biological drugs and after 24 weeks (T6) for sample in co-medication therapy.

Results
The two-way ANOVA method was used to evaluate the standard deviations (SD): at T3 and T6 Group B obtained a significant PASI reduction and improvement of DLQI (* p value <0.05) compared to Group A.

Conclusion
Our study shown that the patients treated with biologics in co-medication with topical therapy reached a significantly higher PASI and DQLI compared with those treated with only biologics. Furthermore we observed that the association with topical oinment showed more efficacy in the treatment of areas such as palm-plantar region, that is often difficult-to-treat region, even for biologic drugs.

PDF